Roadmap for developing and validating therapeutically relevant genomic classifiers.

Oncologists need improved tools for selecting treatments for individual patients. The development of therapeutically relevant prognostic markers has traditionally been slowed by poor study design, inconsistent findings, and lack of proper validation studies. Microarray expression profiling provides an exciting new technology for relating tumor gene expression to patient outcome, but it also provides increased challenges for translating initial research findings into robust diagnostics that benefit patients and physicians in therapeutic decision making. This article attempts to clarify some of the misconceptions about the development and validation of multigene expression signature classifiers and highlights the steps needed to move genomic signatures into clinical application as therapeutically relevant and robust diagnostics.

[1]  K R Hess,et al.  Clinical trial design for microarray predictive marker discovery and assessment. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Richard Simon,et al.  When is a genomic classifier ready for prime time? , 2004, Nature Clinical Practice Oncology.

[3]  Stefan Michiels,et al.  Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.

[4]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[5]  Kenneth H Buetow,et al.  Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[7]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Dudoit,et al.  Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data , 2002 .

[9]  E. Wit.  Design and Analysis of DNA Microarray Investigations , 2004, Human Genomics.

[10]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[11]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[12]  Richard M. Simon,et al.  A Paradigm for Class Prediction Using Gene Expression Profiles , 2003, J. Comput. Biol..

[13]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[14]  Geoffrey J McLachlan,et al.  Selection bias in gene extraction on the basis of microarray gene-expression data , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Eiermann.  Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[17]  Annette M. Molinaro,et al.  Prediction error estimation: a comparison of resampling methods , 2005, Bioinform..

[18]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[19]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[20]  Joanna H Shih,et al.  Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[22]  R. Simon,et al.  Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.

[23]  Debjani Dutta,et al.  Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. , 2004, The American journal of pathology.

[24]  J. Baselga.  Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials , 2001, Oncology.

[25]  D. Hand,et al.  Idiot's Bayes—Not So Stupid After All? , 2001 .

[26]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.